Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hemolab Ltd. Co. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to a distinct examiner within a distinct art unit. AFREMOVA, VERA is the busiest examiner for the portfolio, currently managing 1 pending office action. The limited scope of the action across the art unit reflects a highly focused prosecution profile for this company at the USPTO.
The presence of a single examiner for the pending office action indicates that the company's current legal activity is concentrated in a single point of contact. This examiner's role is defined by the one pending matter, as there are no other actions currently active in the portfolio. For a practitioner, this data suggests a streamlined administrative path with no current evidence of examiner overlap or art unit diversity. The focus on a single art unit within the Biotechnology & Pharmaceuticals area suggests that the company's technical interests are not currently diversified across different USPTO departments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AFREMOVA, VERA | 1 | 50.5% | +29.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18713167 | COMPOSITION INCLUDING MICROBIAL HEMOPROTEIN EXTRACT FOR IMPROVING INTESTINAL FUNCTION AND OBESITY | AFREMOVA, VERA | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713167 | COMPOSITION INCLUDING MICROBIAL HEMOPROTEIN EXTRACT FOR IMPROVING INTESTINAL FUNCTION AND OBESITY | AFREMOVA, VERA | 1653 | §103 | Non-Final OA | — | Pending | May 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial